(Albany, United States) As per DelveInsight’s assessment, globally, the Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Chronic Obstructive Pulmonary Disease pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, Chronic Obstructive Pulmonary Disease NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Chronic Obstructive Pulmonary Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Key Takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report

• DelveInsight’s Chronic Obstructive Pulmonary Disease Pipeline analysis depicts a robust space with 65+ active players working to develop 70+ pipeline treatment therapies.
• The leading Chronic Obstructive Pulmonary Disease Companies are working in the market include Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others
• Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies in the various stages of development include Astegolimab, REGEND001 Autologous Therapy Product, High dose or normal dose staphylococcus albicans, Ensifentrine, Benralizumab, Tiotropium Bromide Combined With Odaterol, and others.
• On June 2023, Sanofi has announced drug named Itepekimab SAR440340 by the phase 3. Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD.
• On March 2023, Nuance Pharma Co. Ltd has announced drug named Ensifentrine by the phase 3. This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks treatment of moderate to severe COPD. The study is divided into 3 periods, a screening/run-in period (run-in for 28 days), a treatment period (24 weeks), and a follow-up period (1 week after the end-of-treatment visit).

 

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases.

 

For further information, refer to the detailed Chronic Obstructive Pulmonary Disease Unmet Needs, click here for Chronic Obstructive Pulmonary Disease Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Chronic Obstructive Pulmonary Disease Emerging Drugs Profile

• Benralizumab: AstraZeneca
• Dupilumab: Sanofi
• Tezepelumab: Amgen
• SNG001: Synairgen
• GSK3923868: GlaxoSmithKline

 

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

There are approx. 65+ Chronic Obstructive Pulmonary Disease companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The Chronic Obstructive Pulmonary Disease companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

Request a sample and discover the recent advances in Chronic Obstructive Pulmonary Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Chronic Obstructive Pulmonary Disease Drugs and Companies

• Endo Pharmaceuticals: Trospium Chloride Inhalation Power
• AstraZeneca: Roflumilast
• Mylan Inc: TD-4208 700 pg
• Viatris Inc: Ipratropium 500 pg
• Astellas Pharma Inc: Reldesemtiv
• Nuance Pharma Co. Ltd: Ensifentrine
• Sanofi: Itepekimab SAR440340

 

Chronic Obstructive Pulmonary Disease Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include-

Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others.

 

Dive deep into rich insights for drugs for Chronic Obstructive Pulmonary Disease Pipeline, click here for Chronic Obstructive Pulmonary Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report

• Coverage- Global
• Chronic Obstructive Pulmonary Disease Companies- Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others.
• Chronic Obstructive Pulmonary Disease Therapies- Astegolimab, REGEND001 Autologous Therapy Product, High dose or normal dose staphylococcus albicans, Ensifentrine, Benralizumab, Tiotropium Bromide Combined With Odaterol, and others
• Chronic Obstructive Pulmonary Disease Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Chronic Obstructive Pulmonary Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tezepelumab: Amgen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GSK3923868: GlaxoSmithKline
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Obstructive Pulmonary Disease- Unmet Needs
21. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
22. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment